Webinars & Online Seminars

What will be covered?

• How PathHunter services save development time compared to in-house assays
• Screening and profiling biologics with highly specific and sensitive assays that produce robust and reproducible results
• Example data from marketed drugs, like Pembrolizumab and Nivolumab, using these cell-based assays

What will be covered?

• RTK biology and drug discovery importance
• Tools needed to create your own RTK cell lines and assays
• Experimental design and workflows
• Applications of RTK and related cell-based assays

What will be covered?

• Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
• Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
• Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells

What will be covered?

• Overview of compound-target engagement
• Tools needed to create your own target engagement assay
• Experimental design and workflow
• Applications of InCELL Pulse assays

What will be covered?

• Screening approaches for GPCR drug discovery
• Creating a duplexed assay to monitor calcium and β-arrestin in a single well

• Determine potential bias for various drugs and define potency ranking

What will be covered?

• Challenges in immuno-oncology drug development
• Tools to expedite and simplify any immuno-oncology drug development pipeline

What will be covered?

• Overview of the BioMAP® immuno-oncology/oncology systems
• Information BioMAP iOnc studies provide
• Host stromal/vascular - tumor microenvironment biology
• Case studies of profiling Ab therapies (anti-PD-1, anti-CTLA-4, etc.) and preclinical compounds

What will be covered?

• Overview of the BioMAP Diversity PLUS phenotypic screening platform's modeling of broad human tissue and disease biology
• Details of how Diversity PLUS profiling guides new indications for marketed drugs and pre-clinical candidates
• Examples highlighting how this technology is used to support repositioning of approved drugs for alternate indications

What will be covered?

• How to maximize knowledge of your compounds using the BioMAP^® Diversity PLUS™ panel of human primary cells systems
• How to understand mechanism classification analysis and toxicity signatures
• A case study on discovery of a mechanism-based novel signature for skin irritation